Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At ...

Chinese technology stocks slumped as the country’s economy worsened. That changed when U.S. tariffs against China fell to ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.

CoV-2, which can enter human cells using the same gateway as the highly contagious SAR-CoV-2 virus that causes COVID-19.

Stocks of makers of COVID vaccines, Moderna MRNA, Pfizer PFE, Novavax NVAX and BioNTech BNTX rose on Friday on reports of a new bat coronavirus being discovered in China. What is the New Coronavirus?

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The stock's fall snapped a three-day winning streak.